-+ 0.00%
-+ 0.00%
-+ 0.00%

Gogin Capital’s Gogin Goenmusubi No. 1 Fund takes minority stake in Neusignal Therapeutics via share subscription

PUBT·06/30/2026 00:01:28
Listen to the news
Gogin Capital’s Gogin Goenmusubi No. 1 Fund takes minority stake in Neusignal Therapeutics via share subscription
  • Gogin Capital’s Gogin Goenmusubi No. 1 Fund invested in Neusignal Therapeutics via a third-party allotment share subscription.
  • Neusignal develops next-generation Alzheimer’s drugs; management cites potential symptom-improvement and disease-progression slowing effects.
  • Neusignal was founded in April 2022; it is based in Tokyo’s Nihonbashi district.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gogin Capital Co Ltd published the original content used to generate this news brief on June 30, 2026, and is solely responsible for the information contained therein.